Cyfuse Biomedical KK's total inventories for the quarter that ended in Dec. 2025 was 円88.74 Mil. Cyfuse Biomedical KK's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Dec. 2025 was 円74.03 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cyfuse Biomedical KK's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was 円235.81.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Cyfuse Biomedical KK's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cyfuse Biomedical KK (TSE:4892) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Cyfuse Biomedical KK's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cyfuse Biomedical KK's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Cyfuse Biomedical KK Total Inventories Related Terms
Cyfuse Biomedical KK Total Inventories Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Cyfuse Biomedical KK (TSE:4892) has a Total Inventories of 円88.74 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Cyfuse Biomedical KK and its competitors.
Is Cyfuse Biomedical KK's Total Inventories too high?
Cyfuse Biomedical KK's current Total Inventories is 円88.74 Mil. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Total Inventories compare to ZTS and UTHR?
Cyfuse Biomedical KK's Total Inventories of 円88.74 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Cyfuse Biomedical KK and its competitors. Cyfuse Biomedical KK's current Total Inventories is 円88.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,179.63, compared to a current price of 円552.00 — trading 74.7% below its estimated fair value. The current Total Inventories is 円88.74 Mil. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Total Inventories is 円88.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円552.00 is trading 74.7% below its estimated GF Value™ of 円2,179.63.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Total Inventories: 円88.74 Mil
GF Value™: 円2,179.63 vs. price of 円552.00 (74.7% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
